Merotrax

Merotrax injection is indicated for treatment in adults and children for the following infections caused by single or multiple bacteria sensitive to Merotrax.

• Pneumonia and Nosocomial Pneumonia
• Urinary Tract Infections
• Intra-abdominal Infections

Gynaecological Infections, such as endometritis and pelvic inflammatory disease

... Read more Merotrax injection is indicated for treatment in adults and children for the following infections caused by single or multiple bacteria sensitive to Merotrax.

• Pneumonia and Nosocomial Pneumonia
• Urinary Tract Infections
• Intra-abdominal Infections

Gynaecological Infections, such as endometritis and pelvic inflammatory disease

• Skin and Skin Structure Infections
• Meningitis
• Septicaemia
• Pulmonary infections in cystic fibrosis

Empiric treatment for presumed infections in patients with febrile neutropenia.

Meropenem is a carbapenem antibiotic for parenteral use . It exerts its bactericidal action by interfering with bacterial cell wall synthesis. It penetrates bacterial cell walls, its high level of stability to all serine beta-lactamases and its marked affinity for the Penicillin Binding Proteins (PBPs.). It shows potent bactericidal activity against a broad spectrum of Gram-positive and Gram-negative, aerobic and anaerobic bacteria.

The dosage and duration of therapy shall be established depending on type, severity of infection and the condition of the patient. The recommended daily dosage is as follows- Adults:

The usual dose is 500 mg to 1 gm by intravenous administration every 8 hours.

Pneumonia, urinary tract infections, gynaecological infections such as endometritis, pelvic inflammatory disease, skin and skin structure infections: 500 mg IV every 8 hours.

Nosocomial pneumonias, peritonitis, presumed infections in neutropenic patients and septicaemia: 1 g IV every 8 hours.

Intra-abdominal infections: 500 mg to 1 gm every 8 hours.

Cystic fibrosis: Upto 2 gm every 8 hours.

Meningitis: 2 gm IV every 8 hours.

Children:

3 months to 12 years: 10 to 40 mg/kg intravenously every 8 hours depending on type and severity of infection, susceptibility of the pathogens and the condition of the patient.

Intra-abdominal infections: 20 mg/kg every 8 hours.

Cystic fibrosis (4-18 years): 25-40 mg/kg every 8 hours.

Meningitis: 40 mg/kg IV every 8 hours.

Febrile neutropenia: 20 mg/kg every 8 hours.

Children over 50 kg weight: use adult dosage.

There is no experience in children with hepatic or renal impairment.

Probenecid competes with Merotrax for active tubular secretion and thus inhibits the renal excretion, with the effect of increasing the elimination half-life and plasma concentration of meropenem. Merotrax may reduce serum valproic acid levels. Sub therapeutic levels may be reached in some patients.

Meropenem is contraindicated in patients who have demonstrated hypersensitivity to this product.

Merotrax is generally well tolerated. Side effects like inflammation, thrombophlebitis, pain at the site of injection, skin reactions like rash, pruritus, urticaria, abdominal pain, nausea, vomiting, diarrhea, headache may occur.

Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. So this drug should be used during pregnancy only if clearly needed. Because many drugs are excreted in human milk, caution should be exercised when Meropenem is administered to a nursing woman.

If an allergic reaction to Merotrax occurs, the drug should be discontinued and appropriate measures taken. Use of Merotrax in patients with hepatic disease should be made with careful monitoring of transaminase and bilirubin levels.

Accidental overdose could occur during therapy, particularly in patients with renal impairment. Treatment of overdose should be symptomatic. In normal individuals, rapid renal elimination will occur; in subjects with renal impairment, haemodialysis will remove Merotrax and its metabolite.

Vial store in a cool, dry place (below 30 o C), away from light & moisture. Keep out of the reach of children.